A5017925159- Prostate Cancer Treatment and Research
- Bone health and treatments
- Radiopharmaceutical Chemistry and Applications
- Cancer Diagnosis and Treatment
- Bone health and osteoporosis research
- Advanced MRI Techniques and Applications
- Medical Imaging Techniques and Applications
- Hormonal and reproductive studies
- Cancer Genomics and Diagnostics
- Cancer, Lipids, and Metabolism
- Cell Adhesion Molecules Research
- CAR-T cell therapy research
- Medical Imaging and Pathology Studies
- MRI in cancer diagnosis
- Particle physics theoretical and experimental studies
- Astronomy and Astrophysical Research
- Management of metastatic bone disease
- Cancer Treatment and Pharmacology
- Prostate Cancer Diagnosis and Treatment
- Bone and Joint Diseases
- COVID-19 epidemiological studies
- Respiratory viral infections research
- Sexual Differentiation and Disorders
- Influenza Virus Research Studies
- Cancer Mechanisms and Therapy
University of Michigan
2024-2025
Harvard University
2003-2024
Massachusetts General Hospital
2011-2024
University of Washington
2024
Vanderbilt University Medical Center
2024
Mayo Clinic in Arizona
2022
Dalhousie University
2022
University of Arkansas at Fayetteville
2022
Center for Astrophysics Harvard & Smithsonian
2022
Thomas Jefferson National Accelerator Facility
2022
Androgen-deprivation therapy is well-established for treating prostate cancer but associated with bone loss and an increased risk of fracture. We investigated the effects denosumab, a fully human monoclonal antibody against receptor activator nuclear factor-κB ligand, on mineral density fractures in men receiving androgen-deprivation nonmetastatic cancer.
Whether bone markers have prognostic value in patients with metastases is unknown. We investigated this question secondary to prostate cancer and non-small-cell lung (NSCLC) other solid tumors assigned the placebo arms of two phase III trials zoledronic acid.Levels urinary resorption marker N-telopeptide serum formation bone-specific alkaline phosphatase were assessed every 3 months for (n = 203) or NSCLC 238) categorized as low high. Patients monitored skeletal-related events, disease...
Three large, randomized trials of patients with bone metastases recently demonstrated that zoledronic acid reduces the risk skeletal-related events. These provide an opportunity for investigating correlation between metabolism and clinical outcome during bisphosphonate therapy.Urinary measurements N-telopeptide (Ntx) serum alkaline phosphatase (BAP) were obtained in 1,824 bisphosphonate-treated patients-1,462 (breast, 490; prostate, 411; myeloma, 210; non-small-cell lung, 183; other, 168)...
Darolutamide is a structurally distinct androgen-receptor inhibitor that approved for the treatment of nonmetastatic, castration-resistant prostate cancer. In planned primary analysis phase 3 trial, median metastasis-free survival was significantly longer with darolutamide (40.4 months) than placebo (18.4 months). The data overall were immature at time analysis.
GnRH agonists decrease bone mineral density and increase fracture risk in men with prostate cancer. Raloxifene increases postmenopausal women, but its efficacy hypogonadal is not known. In a 12-month open-label study, nonmetastatic cancer (n = 48) who were receiving agonist assigned randomly to raloxifene (60 mg/d) or no raloxifene. Bone densities of the posteroanterior lumbar spine proximal femur measured by dual energy x-ray absorptiometry. Mean (+/-se) increased 1.0 +/- 0.9% treated...
Bone health and maintenance of bone integrity are important components comprehensive cancer care in both early late stages disease. Risk factors for osteoporosis increased patients with cancer, including women chemotherapy-induced ovarian failure, those treated aromatase inhibitors breast men receiving androgen-deprivation therapy prostate undergoing glucocorticoid therapy. The skeleton is a common site metastatic recurrence, skeletal-related events the cause significant morbidity. National...
Androgen deprivation therapy is associated with fracture risk in men prostate cancer. We assessed the effects of toremifene, a selective estrogen receptor modulator, on incidence receiving androgen during 2-year period.
The role of viral interaction—where one virus enhances or inhibits infection with another virus—in respiratory transmission is not well characterized. This study used data from 4029 total participants 957 households who participated in a prospective household cohort Southeast Michigan, U.S.A to examine how coinfection and cocirculation may impact symptomatic influenza syncytial infections. We utilized multivariable mixed effects regression estimate risk when index cases were coinfected...
No AccessJournal of UrologyAdult Urology1 Oct 2010Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Canceris corrected byErratumis companion ofToremifene Cancer Matthew R. Smith, Ronald A. Morton, K. Gary Barnette, Paul Sieber, S. Bruce Malkowicz, Domingo Rodriguez, Michael L. Hancock, and Mitchell Steiner SmithMatthew Smith Massachusetts General Hospital Center, Boston, , MortonRonald Morton GTx Incorporated, Memphis, Tennessee BarnetteK. Barnette...
Learning Objectives After completing this course, the reader will be able to: Describe benefits of bisphosphonate treatment in patients with bone metastases from breast cancer.Summarize association between decreases elevated urinary NTX levels during first 3 months zoledronic acid and clinical outcomes such as survival, time to disease progression, SRE.Describe association, if any, marker an impending SRE. Access take CME test online receive 1 AMA PRA Category Credit™ at CME.TheOncologist.com
We investigated associations of baseline cardiovascular disease risk profile, dosing regimen and treatment duration with incident events during androgen deprivation therapy degarelix in patients prostate cancer.Data on 1,704 men who participated a total 9 clinical trials were pooled for analysis. Patients received 1-month (20 to 240 mg) or 3-month (240 480 doses an average 22 months. End points ischemic heart disease, cerebrovascular disorders, arterial thrombotic/embolic intermittent...
5514 Background: DARO is a structurally distinct androgen receptor inhibitor with favorable safety profile, approved for treating men nmCRPC after demonstrating significantly prolonged metastasis-free survival, compared placebo (PBO), in the phase III ARAMIS trial: median 40.4 vs 18.4 months, respectively (HR 0.41; 95% CI 0.34–0.50; P<0.0001). We report final analyses of OS and prospectively collected, patient-relevant secondary endpoints, updated results. Methods: 1509 patients (pts)...
Binospec is a wide-field optical (360 to 1000 nm) spectrograph commissioned at the MMT 6.5m telescope in 2017. In direct imaging mode addresses twin 8$^\prime$ (wide) by 15$^\prime$ (slit length) fields of view. We describe an fiber based integral field unit (IFU) that remaps 12$^{\prime\prime}$ x 16$^{\prime\prime}$ contiguous region onto two pseudo slits, one each channel. The IFU, 2023, fits into space standard slit mask frame and can be deployed as desired mixed program masks, long IFU...
Abstract Binospec is a wide-field optical (360–1000 nm) spectrograph commissioned at the MMT 6.5 m telescope in 2017. In direct imaging mode addresses twin <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" overflow="scroll"> <mml:mn>8</mml:mn> <mml:mi>′</mml:mi> </mml:math> (wide) by <mml:mn>15</mml:mn> (slit length) fields of view. We describe an fiber based integral field unit (IFU) that remaps 12″ × 16″ contiguous region onto two pseudo slits, one each channel. The IFU, 2023, fits...
OBJECTIVE To evaluate mifepristone (RU‐486) in patients with castration‐resistant prostate cancer (CRPC), a correlative assessment of serum androgens and androgen metabolites PATIENTS AND METHODS The receptor (AR) is critical the development progression cancer, but available antiandrogens incompletely abrogate AR signalling. Mifepristone potent antagonist that functions by competing androgen, preventing coactivator binding enhancing corepressors. Patients CRPC were treated 200 mg/day oral...
Abstract Purpose: Bone antiresorptive agents can significantly reduce bone turnover markers (BTM) in patients with advanced cancer. We evaluated association of changes BTMs overall survival (OS), disease progression (DP), and (DPB) cancer metastases following denosumab or zoledronic acid treatment. Experimental Design: This is an integrated analysis patient-level data from three identically designed, blinded, phase III trials randomized to subcutaneous intravenous acid. Levels the urinary...
Zoledronic acid (ZOL) is an important component of therapy for patients with metastatic bone disease (MBD) to reduce the risk skeletal-related events (SREs). We evaluated overall survival (OS) in MBD secondary solid tumours included placebocontrolled ZOL trials. Exploratory analyses were performed using databases from three randomised trials versus placebo. 1126 (ZOL, n=731; placebo, n=395) complete baseline data 18 predefined parameters OS. Relative risks (RRs) 95% confidence intervals...